
Effect of Helicobacter Pylori Infection on Upper Air Way and Alimentary Tract Related Clinical Presentation in Gastroesophageal Reflux Disease

Ebrahiem A. Bofares,* Khalid. M. Bofares,**

Abstract:

Back ground and objectives: Gastro esophageal reflux disease (GERD) is believed to be important contributing factor in many disorders of upper respiratory and alimentary tracts namely rhinosinusitis nasal polyps, adenoid enlargement, chronic tonsillitis, chronic pharyngitis, chronic esophagitis, esophageal strictures, chronic laryngitis, otitis media, and chronic chest infections. It has been reported that GERD and Helicobacter pylori infection may be interrelated phenomena. Although there are many theories tried to explain the pathogenesis of GERD but still Helicobacter pylori based theory is considered as strong theory via which the GERD pathophysiological mechanism factor can be presented. The successful eradication of Helicobacter pylori infection was shown to be significantly related to improvement of the symptomatology in patients with chronic upper air way and alimentary tract related disorders. Therefore this study was conducted prospectively to confirm this concept.

Materials and methods: Two hundred and thirty five patients aged 5-85 years of different GERD stages presented with varieties of upper air way and alimentary tracts related clinical presentations underwent serological examination for Helicobacter pylori before and after eradication medication of infection.

Results: Two hundred and eight patients (89%) of the total number showed positive Helicobacter pylori and 203 cases (98%) were improved after medical eradication course against Helicobacter pylori. On the other hand only 27 patients (11%) with either upper air way or alimentary tract related disorders were found to have negative Helicobacter pylori results.

Conclusion: Helicobacter pylori infection, as a predisposing factor in the pathogenesis of GERD plays a significant role in the incidence of the upper air way as well as upper alimentary tract related disorders, and the proper control of Helicobacter colonization will be positively reflected on the clinical status.

Key words: Gerd, Helicobacter Pylori.

Introduction:

Gastro esophageal reflux disease (GERD) is believed to be an important contributing factor in many disorders of upper respiratory and alimentary tracts. It is the most common esophageal disorder.¹

GERD is patho-physiologically developed due to defect in one or more of the normal anatomical or physiological control mechanism factors of the reflux phenomenon resulting in the exceeding of normal reflux index and thus the appearance of the clinical presentation of the disease. Reflux index is considered as time factor of reflux phenomenon occurrence per 24 hours which must be normally not exceeding five minutes.²

Therefore, if the total duration of reflux process is more than the normal upper limit, it includes the reflux disease process and the appearance of GERD symptom-ology.³ The defect in reflux index can be due to anatomical predisposition as lower esophageal sphincter weakness, cardio-phrenic angle anatomical disorders, increasing of the abdominal-thoracic pressure gradient, and phrenoesophageal ligament weakness, and/or physiological predisposition as increasing in gastric secretion rate, defect in gastric acid clearance which can be due to defect in esophageal mobility, defect in salivary basic secretions, and/or defect in esophageal mucosal bridges regeneration and secretions.⁴

*) Department of Medicine, Faculty of Medicine, Omar Almoukhtar University.

**) Otorhinolaryngology Department, Faculty of Medicine, Omar Almoukhtar University.

There are different theories to explain the pathogenesis of the excessive promotion of gastric acid secretions. The most important theories are biliary system disorders based theory, cyclooxygenase -2 (COX-2) enzyme based theory, and helicobacter pylori infection based theory.⁵

Helicobacter pylori plays an important role in the pathogenesis of GERD.⁶ It was isolated from different places of alimentary as well as respiratory tract of patients who were diagnosed as GERD.⁷ Among those patients, the control of the clinical conditions was directly proportional to the eradication of the bacteria.⁸

H. pylori is a gram negative microaerophilic, rod-shaped bacteria approximately 0.5nm in diameter and 3-5nm long.⁹ H. pylori has 4-7 polar-sheathed flagella, which enable the bacterium to move freely in viscous environment such as gastric mucus. This motility is essential for the bacterial colonization of its host. The flagella sheath is a membrane containing protein and lipo - polysaccharides which probably protects the flagella filaments from gastric acidity.¹⁰

It is well recognized that stomach is the natural niche for H. pylori, despite the fact that its environment with highly concentrated hydrochloric acid hostile for most other bacteria including H. pylori, as gastric acid is to serve as a defense factor aimed to kill bacteria passing the stomach with contaminating food.^{11,12}

H. pylori is exceptionally adapted to survive and grow in acid environment of gastric juice.¹³ It hides itself from direct exposure to gastric acid because it develops several mechanisms preventing detrimental influence of acid by: 1. Moving under the mucus layer covering the surface mucosal epithelial cells, which additionally secretes bicarbonate (HCO₃) to create alkaline environment. 2. H. pylori has high urease activity producing alkaline ammonia to neutralize hydrogen (H⁺) around the germ. 3. Ammonia creates alkaline milieu around H. pylori cell and shields it from direct action of acid. Thus, the bacteria are extremely well adapted to the acidic milieu of the stomach, this is why the H. pylori infection once acquired, usually during childhood, remains for decades or even throughout lifetime.¹⁴

H. pylori has great ability to survive and reemerge as micro evolved strain after being eradicated. So follow up of patients after therapy is required.¹⁵

H. pylori is nutritionally fastidious and can be cultivated on defined media as blood agar, under microaerophilic condition or the presence of air enriched with 10%carbon dioxide. Optimal growth is obtained at 37°C after 4-5 days for primary culture or 2 days for subsequent subculture. It is catalase and oxidase positive.¹⁶

H. pylori can degrade lipids as sources of carbon, phosphate and energy.¹⁷ In addition, it can grow depending on the culture medium over a wide range of pH 5.5-8.5 with good growth between pH 6.9 and 8.¹⁸ Helicobacter pylori infection is usually acquired in childhood and persists for life unless specifically eradicated, yet, it can emerge after eradication.¹⁹

In developing countries, the major risk factor for acquiring H. pylori infection is poor socioeconomic condition during childhood. Therefore prevalence of H. pylori infection can be greater than 80% in children less than 10 years old and up to 90% in adult.²⁰

In contrast children develop few infections in developed countries. A gradual increase in prevalence is observed with age with infection rates of 20-30% by age of 20 and of about 50% at 50-60 years.²²

Poor socioeconomic condition during early childhood as measured by household crowding and parental income are thought to play some role in H. pylori infection.²³

There is evidence that countries with poor sanitation have greater infection rates which suggests a common water source as the reservoir rather than person to person transmission. There is a strong correlation between consumption of municipal water and H. pylori infection in some countries. Recent data suggest that the bacterium is present in river water and drinking water.²⁴

H. pylori infection is significantly higher in males than females. It was found that smoking did not cause ulcer in absence of H. pylori infection.²⁵ The genetic factors may influence disease prevalence, however, as evidenced by

H. pylori concordance being higher in monozygotic than dizygotic twins.²⁶ The sources and routes of transmission have not been definitively established despite numerous studies which suggest that faecal-oral and oral-oral transmission of *H. pylori* is most likely.²⁷

In addition to gastric specimens, detection of *H. pylori* from different regions such as oral region suggests that bacterium may lead to a broad spectrum of clinical manifestations and may be the cause of the high incidence of *H. pylori* infection in the world.²⁸ Recent data showed that *H. pylori* was associated with extra gastric disorders such as coronary heart disease, rosacea,²⁹ glaucoma³⁰ chronic rhinosinusitis³¹ and squamous cell carcinoma of the head and neck.³² Compared with control subjects, a significantly higher prevalence of *H. pylori* in patients with these disorders were documented. Other evidence regarding the association of *H. pylori* with these disorders was the improvement in the conditions of some patients after eradication of *H. pylori*.³³ Several clinical observation suggest role for *H. pylori* infection in various immunological disorders. Some reports have shown healing of some autoimmune disease such as henoch-schonlein purpura SjOgren's and autoimmune thrombocytopenia after eradication of *H. pylori*.³⁴

Further-more, the observation of complete disappearance of some cases of extragastric mucosa associated lymphoid tissue (MALT) lymphoma, such as those localized to the salivary gland, small intestine and rectum, following treatment for *H. pylori* infection is of special interest.³⁵

Some studies have suggested a link between idiopathic chronic urticaria and *H. pylori* infection. A recent study in particular showed a significant decrease in the typical symptoms of urticaria, such as wheals, erythema and pruritus after eradication of *H. pylori*.³⁶ The reasons behind the phenomenon however are unknown. Probably, an increase in mast cell degranulation, which could be induced by *H. pylori* cytotoxic strains, may act as a trigger in subjects with an individual susceptibility to develop urticaria. Acne rosacea and alopecia areata have also been associated with *H. pylori* infection.³⁷

H. pylori infection is reported to be more highly prevent in patients with sideropenic

anaemia compared with healthy controls.³⁸ Recently, a higher prevalence of *H. pylori* infection has been described in patients with liver cirrhosis than in age and sex matched controls.³⁹ A possible link between pylori infections and some diseases of the biliary tract has been hypothesised. In particular, a recent study showed the presence of *H. pylori* sequences in bile samples however, whether *H. pylori* is associated with cholelithiasis is not known.⁴⁰

Some studies showed that *H. pylori* seropositivity was associated with late menarche, slower growth rate in girls infected with *H. pylori*.⁴¹ At least 25 epidemiological studies have been published on the association between *H. pylori* antibody titer and ischemic heart disease.⁴² More recently, it has been suggested to play a pathogenic role in migraine, based on a relationship between the host immune response against the bacterium and the alterations of vascular permeability as a result of chronic release of vasoactive substances; superoxide radicals and nitric oxide during the infection.⁴³ It is confirmed that focal T-cell mediated immunity (delayed type of hypersensitivity reaction or a cytotoxic response) is the mechanism- ultimately responsible for tissue destruction in the recurrent aphthous ulcer.⁴⁴ It had been suggested that this mechanism is induced by *H.pylori* infection.⁴⁵

Recently a high prevalence of *H. pylori* infection has been recognized in patients with chronic open angle glaucoma. *H. pylori* infection may influence the pathophysiology of glaucoma by releasing various vasoactive substances.⁴⁶ *H. pylori* was shown in the upper aerodigestive tract in several studies; this indicates that it might be related to the pathogenesis of various ear, nose and throat diseases. *H. pylori* was detected in the nasal and sinus mucosa of patients with chronic sinusitis which indicates a possible role in pathogenesis of chronic sinusitis.^{47,48}

Furthermore, *H. pylori* was detected in nasal polyp tissue. The mechanism by which *H. pylori* reaches the nasal cavity can be explained by three possibilities. First, the nasal cavity may be a reservoir of *H. pylori*. Second, the oral cavity may represent the reservoir of *H. pylori* and the microorganisms may come to the sinonasal cavity by way of the oronasal reflux. Third, the stomach may be the primary

reservoir of this infection, and transmission of *H. pylori* from the stomach to the nasal cavity might occur by way of Gastroesophageal reflux (GERD).⁴⁹

However reflux is believed to be an important contributing factor in many disorders of the upper respiratory tract particularly sinusitis.⁵⁰ although the mechanism of how the GERD causes sinusitis is unclear, we do know that acid exposure results in mucosal edema secretion in respiratory mucosa, and chronic inflammation. It has been shown that *H. pylori* bacterium is an inflammatory cofactor similarly to GERD. The *H. pylori* can promote inflammation, increase production of interleukin-1 alter the sinonasal mucosa, and also contribute to the reactive hyperplasia of the epithelium, which can lead to the formation of polyps. It has been reported that GERD and *H. pylori* colonization may be a interrelated phenomenon.⁵¹

Chronic pharyngitis may be related to *H. pylori* infection. The infection rate with *H. pylori* in the pharynx is higher in patients with stomach ailment histories than in patients without stomach ailment histories.⁵²

In recent years, gastroesophageal reflux has been increasingly associated with chronic middle ear problems but the underlying mechanism is unclear.⁵³ The demonstration of *H. pylori* in the middle ear indicates that gastric contents reach the middle ear due to reflux and supports that reflux and *H. pylori* may be involved in the pathogenesis of OME resistant to medical treatment. However, it may be postulated that *H. pylori* may cause secretory hyperplasia in the middle ear just as it does in the gastric mucosa.⁵⁴ Tasker et al⁵⁵ determined higher concentration of pepsin and dehsinogen in the middle ear than serum of patients with OME indicating that gastric juice could reach as far as middle ear.⁵⁶ If gastric juice could enter the middle ear, *H. pylori* a common inhabitant of gastric juice and mucosa in patients with peptic ulcer and chronic gastritis, would also be expected to be found in the middle ear of patients with OME.⁵⁷ Reflux of gastric content from the nasopharynx into the middle ear is, possibly, due to the angle of the immature eustachian tube this would cause inflammation of the nasopharynx and eustachian tube.⁵⁸

Disturbing eustachian tube clearance, thus

causing the nasopharyngeal bacteria to enter the middle ear. *H. pylori* may be one of such bacterium. Resolution of OME with antibiotics also supports this hypothesis. In cases of sinusitis and OME resistant to medical and surgical treatment, gastroesophageal reflux and *H. pylori* infection should be considered and evaluated.⁵⁹

Various testes are available to diagnose *H. pylori* infection. These testes can be categorized into those that are based on direct assessment of biopsies specimens and indirect tests that detect an immunological response (i.e antibodies against *H. pylori*) or metabolic products (urease activity) of *H. pylori*. The gold standard for the detection of *H. pylori* has been defined as culture, histopathological examination of biopsy specimen or serology, depending on the experience of investigator. In order to optimize the diagnosis of *H. pylori*, it is usually recommended that several tests to be used together.^{60,61} Biopsy specimen is required for (rapid urease test, microbiological, histological and polymerase chain rection (PCR assay).⁶² On the other hand the indirect non invasive tests will include The urea breath test which is based on urease activity of the organism which liberates carbon dioxide (CO₂) from urea and produces ammonia to buffer its acidic environment,⁶³ and Several serological techniques have been used for the study *H. pylori* infection (e.g. complement fixation haemagglutination test, immunoblot, fluroimmunoassay) but enzyme-linked immunosorbent assay (ELISA) is currently considered as the optimal serological method.⁶⁴

Eradication of *Helicobacter pylori* is defined as the absence of the organisms for least a month after cessation of medication.⁶⁵ Successful eradication of *Helicobacter pylori* infection was shown to be significantly related to improvement of the symptomatology in the patients with chronic gastritis, duodenal and gastric ulcers and has been even associated with regression of B-cell gastric lymphoma.^{65,66}

Helicobacter pylori can be eradicated from the body with proton pump inhibitors with 2 or 3 antibiotic combinations for 2 weeks. With 3 (omeprazole, clarithromycin, amoxicillin or 4 (omeprazole, clarithromycin, amoxicillin, metronidazole) drug combinations, eradication rates of 75% to 88% or 80% to 99% can be achieved, respectively.⁵³

Patients and Methods:

Two hundred and thirty five patients aged 5-85 years with already confirmed GERD at different grades according to (Savary- Millar or Savary- Monnier 1989) grading system on bases of diagnostic upper gastrointestinal tract fibroptic endoscopic evaluating examination presented at internal medicine department and ENT department, Althwora-hospital, Elbedya-Libya with varieties of upper aerodigestive related symptoms at period from September 2005 up to March 2009 were studied as prospective study .All patients were investigated for H.pylori infection by using of ELISA as serological test to demonstrate anti-helicobacter pylori antibodies titer before the starting of the recommended medication and compared with results at the end of the course by 4-6 months. The results were correlated with the clinical presentations of the patients. Patients who had used antacids, H₂-blockers or antibiotics during the month preceeding the presentation were excluded. An informed consent was taken from the patients or the parents of the children involved in the research prior to their participation.

Data were expressed by using descriptive analysis as means $\pm$ standard error of mean (s. e. m) and percentages, test of significance was carried out, using Chi-squar test and two way analysis of variance⁽³⁾. A probability less than 0.05 was considered as significant, the degree of significance was determined by using level of standard deviation test. Student -t- test was used for dependent sample, as well as contingency coefficient was calculated as measurement of association between nominal variables.

Results:

As shown in (Table I) there were 96 males and 139 females. The age distribution showed that 62% of cases were > 40 years of age. On the other hand 23% of the patients were of age <15 years ($P < 0.05$). Regarding the clinical presentation, the most frequent clinical presentation was laryngeal related disorders presentation (53%), followed by sinopathic related symptomology (49%), then aural and upper alimentary tract related presentation (19%) as shown in (Table III).

As demonstrated in (Table IV), in large number of cases (89%) the patients had a positive ELISA test for H. pylori infection with high significant rate ($P < 0.01$) as compared with 27 cases with negative ELISA test. The titer of the anti-helicobacter antibodies among the patients with positive ELISA is significantly higher (9.135 ± 0.24) than those with negative ELISA test (0.782 ± 0.008) ($P < 0.01$) as showed in (Table IV). Table V presented significant reduction of anti-helcobacter antibodies by 4-6 months from the end of full recommended course of treatment (1.459 ± 0.0327) as compared with the initial titer prior to starting of treatment ($P < 0.01$). The (Table VI) illustrated the significant complete eradication of the bacteria among 203 out of 208(98%) after one month as follow up from the time of confirmed response to the treatment ($P < 0.005$) and was correlated with clinical findings which was showed significant improvement too.

Table I: Sex distribution. ($P < 0.05$).

Sex	Males	Females	Total
No.	96	139	235
Percent	62.5	37.5	100

Table II: Age distribution. ($P < 0.05$).

Age	<15	15-40	40-85
No.	54	35	146
Percent	23	15	62

Table III: Presenting disorders (P < 0.05).

Disorders	%
Laryngitis	53
Chronic sinusitis	49
Chest infection	27
Esophagitis	19
Recurrent otitis media	19
Snoring and sleep apnea syndrome	17
Chronic gastritis	13
Chronic pharyngitis	11.8
Bronchospasm and laryngeal asthma	9
Recurrent aphthous ulcers	8
Cervical torticollus	3
Recurrent nasal polyp	3
Uncontrolled cardiac arhythmias	1.6

Table IV: ELISA results prior to the initiation of the treatment: (P < 0.01).

Result	Positive	Negative
No.	208	27
Anti-body titer (mean + _S.D)	9.135+ _0.24	0.782+ _0.008

Table V: ELISA results after 4-6 months after the treatment: (P < 0.01)

Time of test	Prior to treatment	after treatment
ELISA results (mean + _S.D)	9.135+ _0.24	1.459+ _0.0327

Table IV: ELISA results after one month from the eradication: (P < 0.01)

Results	Complete eradication	Recurrence	Total
No.	203	005	208
Percent	98	2	100

Discussion:

Helicobacter pylori (*H. pylori*) is one of the most common bacterial infections world wide. Estimates suggest that more than half of the world's population is infected by this gastric bacterium.⁴³ It is associated with chronic gastritis and peptic ulcer diseases.^{39,44} and constitutes a major risk factor for gastric adenocarcinoma and gastric mucosa associated lymphoid tissue (MALT) lymphoma.³⁴ Although the stomach is the natural reservoir of *H. pylori* various tissues have been proposed as potential reservoirs of infection such as tonsil, gingiva, dental plate, gallbladder, and coronary arteries.¹²

The presence of *H. pylori* in the upper aerodigestive tract has been investigated in

more than 60 reports in the English literature, some of them examine its presence in the tonsils and/or adenoids by using various diagnostic techniques showed that there was a high rate of *H. pylori* colonization in tonsillar and adenoid tissues however, other indicated opposite results.^{54,62,66}

There are several methods (invasive and non-invasive) available for detecting *H. pylori* infection. Invasive methods are based on biopsy specimens as; Rapid urease test, PCR,⁴⁷ culture staining biopsy materials with H&E stain, Giemsa stain, Warthin-Stany silver stain,⁷⁸ and stains which determine the macrophage iNOS (inducible nitric oxide synthase) activity in tonsillar tissue.²⁹ Non-

invasive methods as; urea breath test,^{80,81} stool antigen test(52)and the enzyme linked immunosorbent assay (ELISA) technique to identify specific immunoglobulin G antibodies against H. pylori in serum.⁶³

When H. pylori was first found to colonize in the upper respiratory tract, investigators used a single diagnostic method to identify H. pylori infection.²⁴ In more recent investigations, multiple tests have been used comparatively in the same study.^{55,56}

Smoot et al (2001) stated that the gold standard in diagnosis of H. pylori infection is the direct identification of the organism by two or more methods from Rapid urease test, culture and histopathology. Ogata et al considered a positive H. pylori infection by combining three or more positive methods (Rapid urease test, serology, histopathology, urea breath test).

The present study was carried on 235 patients. Serum samples from all patients were tested using the ELISA to identify specific immunoglobulin G antibodies against H. pylori. Serology test is used for diagnosis and

follow-up of H. pylori infection and for epidemiological studies. Using ELISA, it is possible to measure anti-H. pylori antibodies of different immunoglobulin classes, and quantitative determinations are possible as well. The IgG is positive in active infection and persists for 4-6 months after eradication of infection.³⁰

It has been reported that serologic testing with ELISA has a sensitivity of 95% and specificity of 100 %.⁴¹ 41% of cases were male while 59% were female. Our findings are against the findings of Blum 1996 who showed that ≥ 78% of cases were male. This can be explained by male to female ratio in the general Libyan population which is showing higher female number as compared to the males. On the other hand our study presented that the percentage of the infection among the children is lower than that in the adult. This is also not in accordance with Kuipers, et al 1993 and Imrie et al 2001.

This can be explained by the presentation of the children to pediatric department rather than ENT or internal medicine department, resulting in the missing of the pediatric cases.

References:

1. Krienitz W. Ueber das Aufireten von Spirochaeten verschiedener form im magenin halt bei Carcinoma ventriculi Dtsch Med Wochenschr. 1906;28:872.
2. Friedberg AS BL. The presence of spirochaetes in human gastric mucosa Am J Dig Dis 1940;7:443-5.
3. Fitzgerald O, Murphy. The urea-urease mechanism as a factor in the depression of gastric acidity and the protection of the mucosa against acid-pepsin. Gastroenterologia. 1950;76(2):86-8.
4. Kornberg HL, Davies RE. Gastric urease. Physiol Rev. 1955 Jan;35(1):169-77.
5. Clearfield HR. Helicobacter pylori: aggressor or innocent bystander? Med Clin North Am. 1991 Jul;75(4):815-29.
6. Steer HW, Cohn-Jones DG. Mucosal changes in gastric ulceration and their response to carbenoxolone sodium. Gut. 1975 Aug;16(8):590-7.
7. Marshall BJ, Warren JR. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. 1983 Jun 4;1 (8336) : 1273-5.
8. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984 Jun 16;1(8390):131 1-5.
9. Romaniuk PJ, Zoltowska B, Trust TJ, Lane DJ, Olsen GJ, Pace NR, et al. Campylobacter pylori, the spiral bacterium associated with human gastritis, is not a true Campylobacter sp. J Bacteriol. 1987 May; 169(5):2137-41.
10. Goodwin CS, Armstrong JA. Microbiological aspects of Helicobacter pylori (Campylobacter pylori). Eur J Clin Microbiol Infect Dis. 1990 Jan;9(1):1-13.
11. Huang JQ, Snidhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology. 1998 Jun;114(6):1 169-79.
12. Glupczynski Y, Burette A, Labbe M, Deprez C, De Reuck M, Deltenre M. Campylobacter pylori-associated gastritis: a double-blind placebo-controlled trial with amoxycillin. Am J Gastroenterol. 1988 Apr;83(4):365-72.
13. Catrenich CE, Makin KM. Characterization of the morphologic conversion of Helicobacter pylori from bacillary to coccoid forms. Scand J Gastroenterol Suppl. 1991;1 81:58-64.
14. Hazell SL, Lee A Brady L, Hennessy W.

- Campylobacter pyloridis and gastritis association with intercellular spaces and adaptation to an environment of mucus as important factors in colonization of the gastric epithelium. *J Infect Dis.* 1986 Apr; 153(4):658-63.
15. Thomas E, Jiang C, Chi DS, Li C, Ferguson DA, Jr. The role of the oral cavity in Helicobacter pylori infection. *Am J Gastroenterol.* 1997 Dec;92(12):2148-54.
 16. Czesnikiewicz-Guzik M, Karczewska E, Bielanski W, Guzik TJ, Kapera P, Targosz A, et al. Association of the presence the Helicobacter pylori in the oral cavity and in the stomach. *J Physiol Pharmacol.* 2004 Jul; 55 Suppl 2:105-15.
 17. Suerbaum S, Michetti P. Helicobacter pylori infection. *N Engl J Med.* 2002 Oct 10;347(15):1 175-86.
 18. Zucca E, Berton F, Roggero B, Bosshard G, Cazzaniga G, Pedrinis E, et al. Molecular analysis of the progression from Helicobacter pylori-associated chronic gastritis to mucosa-associated lymphoid-tissue lymphoma of the stomach. *N Engl J Med.* 1998 Mar 19;338(12):804-10.
 19. Prouzet-Mauleon V, Hussain MA, Lamouliatte H, Kauser F, Megraud F, Ahmed N. Pathogen evolution in vivo: genome dynamics of two isolates obtained 9 years apart from duodenal ulcer patient infected with a single Helicobacter pylori strain. *J Clin Microbiol.* 2005 Aug;43(8): 4237-41.
 20. Windsor HM, O'Rourke J. Bacteriology and taxonomy of Helicobacter pylori. *Gastroenterol Clin North Am.* 2000 Sep; 29(3):633-48.
 21. Hazell SL, Mendz GL. How Helicobacter pylori works: an overview of the metabolism of Helicobacter pylori. *Helicobacter.* 1997 Mar;2(1):1-12.
 22. Morgan DR, Freedman R, Depew CE, Kraft WG. Growth of Campylobacter pylori in liquid media. *J Clin Microbiol.* 1987 Nov; 25(11):2123-5.
 23. Kuipers EJ, Pena AS, van Kamp G, Uytendaele AM, Pals G, Pels NF, et al. Seroconversion for Helicobacter pylori. *Lancet.* 1993 Aug 7;342(8867):328-31.
 24. Imrie C, Rowland M, Bourke B, Drumm B. Is Helicobacter pylori infection in childhood a risk factor for gastric cancer? *Pediatrics.* 2001 Feb;107(2):373-80.
 25. Banatvala N, Lopez CR, Owen R, Abdi Y, Davies O, Hardie J, et al. Helicobacter pylori in dental plaque. *Lancet.* 1993 Feb 6;341(8841):380.
 26. Malaty HM, Graham DY. Importance of childhood socioeconomic status on the current prevalence of Helicobacter pylori infection. *Gut.* 1994 Jun;35(6):742-5.
 27. Akcan Y, Ersan S, Alper M, Bicik Z, Aytug N. The transmission of Helicobacter pylori: via exposure to common sources outweighs the person-to-person contact among spouses in developing countries. *Am J Gastroenterol.* 2000 Jan;95(1):317-9.
 28. Blum AL. Helicobacter pylori and peptic ulcer disease. *Scand J Gastroenterol Suppl.* 1996;214:24-7; discussion 42-3.
 29. Graham DY, Malaty HM, Go MF. Are there susceptible hosts to Helicobacter pylori infection? *Scand J Gastroenterol Suppl.* 1994;205 :6-10.
 30. Bussac G. Helicobacter pylori and the oral environment. *Pract Periodontics Aesthet Dent.* 1999 Oct;11(8):918, 20,22.
 31. Teh BH, Lin JT, Pan WH, Lin SH, Wang LY, Lee IK, et al. Seroprevalence and associated risk factors of Helicobacter pylori infection in Taiwan. *Anticancer Res.* 1999 May-Jun; 19(4B): 1389-92.
 32. Kelly SM, Pitcher MC, Farmery SM, Gibson GR. Isolation of Helicobacter pylori from feces of patients with dyspepsia in the United Kingdom. *Gastroenterology.* 1994 Dec; 107(6): 1671-4.
 33. Li C, Ha T, Ferguson DA, Jr., Chi DS, Zhao R, Patel NR, et al. A newly developed PCR assay of H. pylori in saliva supports oral transmission. *Dig Dis Sci.* 1996 Nov; 41(11): 2142-9.
 34. Riggio MP, Lennon A, Wray D. Detection of Helicobacter pylori DNA in recurrent aphthous stomatitis tissue by PCR. *J Oral Pathol Med.* 2000 Nov;29(10):507-13.
 35. Riggio MP, Lennon A. Identification by PCR of Helicobacter pylori in subgingival plaque of adult periodontitis patients. *J Med Microbiol.* 1999 Mar;48(3):317-22.
 36. Megraud F. Transmission of Helicobacter pylori: faecal-oral versus oral-oral route. *Aliment Pharmacol Ther.* 1995;9 Suppl 2:85-91.
 37. Dnumm B, Perez-Perez UI, Blaser MJ, Sherman PM. Intrafamilial clustering of Helicobacter pylori infection. *N Engl J Med.* 1990 Feb 8;322(6):359-63.
 38. Ishihara K, Miura T, Kimizuka R, Ebihara Y, Mizuno Y, Okuda K. Oral bacteria inhibit Helicobacter pylori growth. *FEMS Microbiol Lett.* 1997 Jul 15;152(2):355-61.
 39. Chong J, Marshall BJ, Barkin JS,

- McCallum RW, Reiner DK, Hoffman SR, et al. Occupational exposure to Helicobacter pylori for the endoscopy professional: a sera epidemiological study. *Am J Gastroenterol*. 1994 Nov;89(11):1987-92.
40. Handt LK, Fox JG, Dewhirst FE, Fraser GJ, Paster BJ, Yan LL, et al. Helicobacter pylori isolated from the domestic cat: public health implications. *Infect Immun*. 1994 Jun;62(6):2367-74.
41. Midolo P, Marshall BJ. Accurate diagnosis of Helicobacter pylori. Urease tests. *Gastroenterol Clin North Am*. 2000 Dec;29(4):871-8.
42. Matsui T, Matsukawa Y, Sakai T, Nakamura K, Aoiike A, Kawai K. Effect of ammonia on cell-cycle progression of human gastric cancer cells. *Eur J Gastroenterol Hepatol*. 1995 Aug;7 Suppl 1:S79-81.
43. Olfat FO, Zheng Q, Oleastro M, Volland P, Boren T, Karttunen R, et al. Correlation of the Helicobacter pylori adherence factor BabA with duodenal ulcer disease in four European countries. *FEMS Immunol Med Microbiol*. 2005 May 1 ;44(2): 151-6.
44. Papadogiannakis N, Willen R, Carlen B, Sjostedt S, Wadstrom I, Gad A. Modes of adherence of Helicobacter pylori to gastric surface epithelium in gastroduodenal disease: possible sequence of events leading to internalisation. *Apmis*. 2000 Jun; 108(6) : 439-47.
45. Moran AP, Lindner B, Walsh EJ. Structural characterization of the lipid A component of Helicobacter pylori rough- and smooth-form lipopolysaccharides. *J Bacteriol*. 1997 Oct; 179(20):6453-63.
46. Appelmek BJ, Simoons-Smit I, Negrini R, Moran AP, Aspinall GO, Forte JG, et al. Potential role of molecular mimicry between Helicobacter pylori lipopolysaccharide and host Lewis blood group antigens in autoimmunity. *Infect Immun*. 1996 Jun;64(6):2031-40.
47. Dunn BE, Cohen H, Blaser MJ. Helicobacter pylori. *Clin Microbiol Rev*. 1997 Oct; 4(4):720-41.
48. Langton SR, Cesareo SD. Helicobacter pylori associated phospholipase A2 activity: factor in peptic ulcer production? *J Clin Pathol*. 1992 Mar;45(3):221-4.
49. Brito CA, Silva LM, Juca N, Lea NC, de Souza W, Queiroz D, et al. Prevalence cagA and vacA genes in isolates from patients with Helicobacter pylori-associated gastroduodenal diseases in Recife, Pernambuco, Brazil. *Mem Inst Oswaldo Cruz*. 2001 Sep;98(6):817-21.
50. Labigne A, de Reuse H. Determinants of Helicobacter pylori pathogenicity. *Infect Agents Dis*. 1996 Oct;5(4): 191-202.
51. Crabtree JE, Farmery SM, Lindley IJ, Figura N, Peichi P, Tompkins DS. CagA/ cytotoxic strains of Helicobacter pylori and interleukin-8 in gastric epithelial cell lines. *J Clin Pathol*. 1994 Oct; 47(10): 945-50.
52. Cover TL. The vacuolating cytotoxin of Helicobacter pylori. *Mol Microbiol*. 1996 Apr;20(2):241-6.
53. Telford JL, Ghiara P, Dell'Orco M, Comanducci M, Burroni D, Bugnoli M, et al. Gene structure of the Helicobacter pylori cytotoxin and evidence of its key role in gastric disease. *J Exp Med*. 1994 May 1; 179(5):1653-58.
54. Peek RM, Jr., Thompson SA, Donahue JP, Tham KT, Atherton JC, Blaser MJ, et al. Adherence to gastric epithelial cells induces expression of a Helicobacter pylori gene, iceA, that is associated with clinical outcome. *Proc Assoc Am Physicians*. 1998 NovDec;110(6):531-44.
55. van Doorn LJ, Figueiredo C, Sanna R, Pena S, Midolo P, Ng EK, et al. Expanding allelic diversity of Helicobacter pylori vacA. *J Clin Microbiol*. 1998 Sep;36(9):2597-603.
56. Fan XG, Chua A, Fan XJ, Kelling PW. Increased gastric production of interleukin-8 and tumour necrosis factor in patients with Helicobacter pylori infection. *J Clin Pathol*. 1995; Feb; 48(2): 133-6.
57. Karttunen R, Karttunen T, Ekre HP, MacDonald TT. Interferon gamma and interleukin-4 secreting cells in the gastric antrum in Helicobacter pylori positive and negative gastritis. *Gut*. 1995 Mar;36(3):341-5.
58. Talley NJ, Newell DG, Onmand JE, Carpenter HA, Wilson WR, Zinsmeister AR, et al. Serodiagnosis of Helicobacter pylori: comparison of enzyme-linked immunosorbent assays. *J Clin Microbiol*. 1991 Aug;29(8):1635-9.
59. Patel P, Mendall MA, Khulusi S, Molineaux N, Levy J, Maxwell JD, et al. Salivary antibodies to Helicobacter pylori: screening dyspeptic patients before endoscopy. *Lancet*. 1994 Aug 20;344(8921):511-2.
60. Craig PM, Ten-ito MC, Karnes WE, Walsh JH. Helicobacter pylori secrete a chemotactic factor for monocytes and neutrophils. *Gut*. 1992 Aug;33(8):1020-3.

61. Ho B, Marshall BJ. Accurate diagnosis of Helicobacter pylori Serologic testing. Gastroenterol Clin North Am. 2000 Dec;29(4):853-62.
62. Alemohammad MM, Foley TJ, Cohen H. Detection of immunoglobulin G antibodies to Helicobacter pylori in urine by an enzyme immunoassay method. J Clin Microbiol. 1993 Aug;31(8):2174-7.
63. Rathbone BJ, Wyatt JI, Worsley BW, Shires SE, Trejdosiewicz LK, Heatley RV, et al. Systemic and local antibody responses to gastric Campylobacter pylonidis in non-ulcer dyspepsia. Gut. 1986 Jun;27(6):642-7.
64. Moms AJ, Au MR, Nicholson GI, Perez-Perez GI, Blaser MJ. Long-term follow-up of voluntary ingestion of Helicobacter pylori. Ann Intern Med. 1991 Apr 15;114(8):662-3.
65. Luzzza F, Maletta M, Imeneo M, Fabiano E, Doldo P, Biancone L, et al. Evidence against an increased risk of Helicobacter pylori infection in dentists: a serological and salivary study. Eur J Gastroenterol Hepatol. 1995 Aug;7(8):773-6.
66. Kosunen TU, Seppala K, Sarna S, Sipponen P. Diagnostic value of decreasing IgG, IgA, and IgM antibody titres after eradication of Helicobacter pylori: Lancet. 1992 April;339(8798):893-5.